טוען...
MON-413 First Reported Case of Combined High-Dose Mifepristone Therapy and Oral Contraceptive in Inducing Reversible Cholestatic Hepatitis in a Patient with Cushing Disease
Background: Cushing syndrome is predisposed to hepatocellular disease due to increased visceral fat resulting in NAFLD, and direct effects of medical therapy, notably ketoconazole. Mifepristone (MIFE) (a competitive glucocorticoid receptor antagonist) is a CYP3A4 inhibitor, whereas loestrin (an oral...
שמור ב:
| הוצא לאור ב: | J Endocr Soc |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Endocrine Society
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6551021/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-MON-413 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|